FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2813643485> ?p ?o ?g. }

• W2813643485 endingPage "1371" @default.
• W2813643485 startingPage "1365" @default.
• W2813643485 abstract "Rivaroxaban is an effective and safe alternative to warfarin in patients with atrial fibrillation and venous thromboembolism. We tested the efficacy and safety of rivaroxaban compared with warfarin in high-risk patients with thrombotic antiphospholipid syndrome. This is a randomized open-label multicenter noninferiority study with blinded end point adjudication. Rivaroxaban, 20 mg once daily (15 mg once daily based on kidney function) was compared with warfarin (international normalized ratio target 2.5) for the prevention of thromboembolic events, major bleeding, and vascular death in patients with antiphospholipid syndrome. Only high-risk patients triple positive for lupus anticoagulant, anti-cardiolipin, and anti-β2-glycoprotein I antibodies of the same isotype (triple positivity) were included in the study. The trial was terminated prematurely after the enrollment of 120 patients (59 randomized to rivaroxaban and 61 to warfarin) because of an excess of events among patients in the rivaroxaban arm. Mean follow-up was 569 days. There were 11 (19%) events in the rivaroxaban group, and 2 (3%) events in the warfarin group. Thromboembolic events occurred in 7 (12%) patients randomized to rivaroxaban (4 ischemic stroke and 3 myocardial infarction), whereas no event was recorded in those randomized to warfarin. Major bleeding occurred in 6 patients: 4 (7%) in the rivaroxaban group and 2 (3%) in the warfarin group. No death was reported. The use of rivaroxaban in high-risk patients with antiphospholipid syndrome was associated with an increased rate of events compared with warfarin, thus showing no benefit and excess risk. This trial was registered at www.clinicaltrials.gov as #NCT02157272." @default.
• W2813643485 created "2018-07-19" @default.
• W2813643485 creator A5003292078 @default.
• W2813643485 creator A5022945946 @default.
• W2813643485 creator A5027676671 @default.
• W2813643485 creator A5032826393 @default.
• W2813643485 creator A5038121597 @default.
• W2813643485 creator A5039927165 @default.
• W2813643485 creator A5044997747 @default.
• W2813643485 creator A5047717272 @default.
• W2813643485 creator A5054015102 @default.
• W2813643485 creator A5058127061 @default.
• W2813643485 creator A5058256497 @default.
• W2813643485 creator A5058320262 @default.
• W2813643485 creator A5060145771 @default.
• W2813643485 creator A5061119590 @default.
• W2813643485 creator A5066934318 @default.
• W2813643485 creator A5067095323 @default.
• W2813643485 creator A5069854712 @default.
• W2813643485 creator A5075020183 @default.
• W2813643485 creator A5075069140 @default.
• W2813643485 creator A5079447134 @default.
• W2813643485 creator A5085761102 @default.
• W2813643485 creator A5087432225 @default.
• W2813643485 date "2018-09-27" @default.
• W2813643485 modified "2023-10-12" @default.
• W2813643485 title "Rivaroxaban vs warfarin in high-risk patients with antiphospholipid syndrome" @default.
• W2813643485 cites W1541122820 @default.
• W2813643485 cites W1668264153 @default.
• W2813643485 cites W1969171402 @default.
• W2813643485 cites W1981957652 @default.
• W2813643485 cites W2017573410 @default.
• W2813643485 cites W2027467473 @default.
• W2813643485 cites W2030684251 @default.
• W2813643485 cites W2041919675 @default.
• W2813643485 cites W2053081517 @default.
• W2813643485 cites W2054330426 @default.
• W2813643485 cites W2059163354 @default.
• W2813643485 cites W2064826963 @default.
• W2813643485 cites W2068265433 @default.
• W2813643485 cites W2069797332 @default.
• W2813643485 cites W2093274439 @default.
• W2813643485 cites W2097854437 @default.
• W2813643485 cites W2109613206 @default.
• W2813643485 cites W2111238248 @default.
• W2813643485 cites W2115787552 @default.
• W2813643485 cites W2117677020 @default.
• W2813643485 cites W2119266650 @default.
• W2813643485 cites W2157458869 @default.
• W2813643485 cites W2158593099 @default.
• W2813643485 cites W2194419520 @default.
• W2813643485 cites W2339926357 @default.
• W2813643485 cites W2373145147 @default.
• W2813643485 cites W2460218540 @default.
• W2813643485 cites W2514539105 @default.
• W2813643485 cites W2547605747 @default.
• W2813643485 cites W2563628618 @default.
• W2813643485 cites W2593137415 @default.
• W2813643485 cites W2791992225 @default.
• W2813643485 cites W2989714602 @default.
• W2813643485 cites W4210593746 @default.
• W2813643485 doi "https://doi.org/10.1182/blood-2018-04-848333" @default.
• W2813643485 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30002145" @default.
• W2813643485 hasPublicationYear "2018" @default.
• W2813643485 type Work @default.
• W2813643485 sameAs 2813643485 @default.
• W2813643485 citedByCount "521" @default.
• W2813643485 countsByYear W28136434852018 @default.
• W2813643485 countsByYear W28136434852019 @default.
• W2813643485 countsByYear W28136434852020 @default.
• W2813643485 countsByYear W28136434852021 @default.
• W2813643485 countsByYear W28136434852022 @default.
• W2813643485 countsByYear W28136434852023 @default.
• W2813643485 crossrefType "journal-article" @default.
• W2813643485 hasAuthorship W2813643485A5003292078 @default.
• W2813643485 hasAuthorship W2813643485A5022945946 @default.
• W2813643485 hasAuthorship W2813643485A5027676671 @default.
• W2813643485 hasAuthorship W2813643485A5032826393 @default.
• W2813643485 hasAuthorship W2813643485A5038121597 @default.
• W2813643485 hasAuthorship W2813643485A5039927165 @default.
• W2813643485 hasAuthorship W2813643485A5044997747 @default.
• W2813643485 hasAuthorship W2813643485A5047717272 @default.
• W2813643485 hasAuthorship W2813643485A5054015102 @default.
• W2813643485 hasAuthorship W2813643485A5058127061 @default.
• W2813643485 hasAuthorship W2813643485A5058256497 @default.
• W2813643485 hasAuthorship W2813643485A5058320262 @default.
• W2813643485 hasAuthorship W2813643485A5060145771 @default.
• W2813643485 hasAuthorship W2813643485A5061119590 @default.
• W2813643485 hasAuthorship W2813643485A5066934318 @default.
• W2813643485 hasAuthorship W2813643485A5067095323 @default.
• W2813643485 hasAuthorship W2813643485A5069854712 @default.
• W2813643485 hasAuthorship W2813643485A5075020183 @default.
• W2813643485 hasAuthorship W2813643485A5075069140 @default.
• W2813643485 hasAuthorship W2813643485A5079447134 @default.
• W2813643485 hasAuthorship W2813643485A5085761102 @default.
• W2813643485 hasAuthorship W2813643485A5087432225 @default.
• W2813643485 hasBestOaLocation W28136434851 @default.
• W2813643485 hasConcept C126322002 @default.

• next